Predicting the Dopamine D2 Receptor Occupancy of Ropinirole in Rats Using Positron Emission Tomography and Pharmacokinetic–pharmacodynamic Modeling

Chenrong Huang,Ziteng Wang,Linsheng Liu,Xiaoxue Liu,Ji Dong,Qingqing Xu,Bin Zhang,Liyan Miao

DOI: https://doi.org/10.1080/00498254.2018.1428383

2018-01-01

Xenobiotica

Abstract:1.The purpose of this study was to measure dopamine D-2/3 receptor occupancy (RO) as a marker of the clinical efficacy of ropinirole in rats via positron emission tomography (PET) using F-18-fallypride as the radiotracer and to explore the relationship between dopamine RO and the plasma concentration of ropinirole via pharmacokinetic-pharmacodynamic modeling. 2.Plasma was collected from 16 rats treated with one of four doses of ropinirole. For the time-dependent study, the data of 16 rats in the 15 mg/kg dose group at four time points were averaged, and another 24 rats were divided into three dose groups (5 mg/kg, 30 mg/kg and 60 mg/kg) for the dose-dependent study; the animals were assessed via F-18-fallypride PET scans. The correlation between dopamine RO and the ropinirole plasma concentration was investigated, and a pharmacokinetic-pharmacodynamic (PK-PD) model was established with WinNonlin 6.3 software. Both the plasma concentration and the binding potential changed in a time- and dose-dependent manner, and the plasma concentration that induces 50% RO (EC50) as calculated by the PK-PD model was 1391 ng/mL. 3.F-18-fallypride appeared to be a suitable radiotracer for ropinirole imaging, and its binding to the dopamine D-2 receptor has time- and concentration-dependent characteristics. A theory-based PK-PD model was developed to describe the relationship between the plasma ropinirole concentration and RO, providing a methodological foundation for noninvasive and in vivo clinical evaluations of ropinirole treatment.